A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act.
Sheantel J ReihlNirav PatilRamin A MorshedMulki MehariAlexander AabediUgonma N ChukwuekeAlyx B PorterValy FontilGino CioffiKristin WaiteCarol KruchkoQuinn OstromJill Barnholtz-SloanShawn L Hervey-JumperPublished in: Neuro-oncology (2022)
Following the Revitalization Act, minorities and women remain underrepresented in therapeutic clinical trials for neuroepithelial tumors, relative to disease incidence and mortality. Study accrual has improved with time. This study provides a framework for clinical trial accrual efforts and offers guidance regarding workforce considerations associated with enrollment of underserved patients.
Keyphrases
- clinical trial
- end stage renal disease
- public health
- polycystic ovary syndrome
- randomized controlled trial
- ejection fraction
- type diabetes
- palliative care
- risk factors
- study protocol
- coronary artery disease
- newly diagnosed
- chronic kidney disease
- open label
- peritoneal dialysis
- insulin resistance
- pregnant women
- phase ii
- quality improvement